RAP ResApp Receives Approval to Begin Adult Study Perth, Western...

RAP
ResApp Receives Approval to Begin Adult
Study
Perth, Western Australia, 14 December 2015 -- ResApp Health Limited (ASX:
RAP), the developer of smartphone medical applications for the diagnosis and
management of respiratory disease, is pleased to announce that it has received
approval to enrol its first adult patient at the Joondalup Health Campus (JHC) in
Perth, Western Australia. The Emergency Department (ED) at JHC provides
emergency services to nearly 100,000 patients per year (80,000 adults and
20,000 children), making it one of Australia’s busiest EDs. The study will gather
data from adults presenting to the ED with respiratory conditions such as upper
respiratory tract infections, bronchitis, pneumonia, asthma and chronic
obstructive pulmonary disease. The aim of the study is to demonstrate that
ResApp’s technology, shown to be highly accurate for diagnosis of childhood
respiratory conditions, can be extended to adults.
JHC Director of Medical Services, Dr Simon Wood said, “We are pleased to again
work with The University of Queensland and ResApp to extend the very
successful childhood study into adult patients. We look forward to seeing how
digital health technologies can be integrated into the practice of medicine and
improve patient care.”
“We are excited to extend our clinical study to adults as an important next step
for the company,” said Dr Tony Keating, CEO and Managing Director of ResApp.
“With over 450 children enrolled in our paediatric study in just eight months, we
have demonstrated the robustness of our machine learning algorithms to
accurately diagnose the majority of childhood respiratory diseases. Including
adults in the JHC study not only provides access to one of Australia’s busiest EDs,
it utilises much of the same clinical team and logistics allowing us to achieve fast
adult patient enrolment.”
ResApp will again work with The University of Queensland to analyse the clinical
data and is targeting enrolment of 400 patients with preliminary results
expected in the first half of calendar 2016.
ResApp plans to extend the adult study to a second site, one of the largest
private emergency departments on the east coast of Australia. In-principle
support has been given and the company plans to submit an application to that
hospital’s Human Research Ethics Committee this month.
- ENDS -